Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.7 ILa | 0.00% | -3.57% | +3.85% |
12/05 | Transcript : Can-Fite BioPharma Ltd. - Special Call | |
09/05 | Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.85% | 10.85M | |
-1.67% | 89.08B | |
+2.76% | 40.9B | |
-12.92% | 32.25B | |
+54.69% | 25.14B | |
-16.51% | 15.39B | |
-8.27% | 11.91B | |
-42.60% | 11.89B | |
-12.82% | 11.64B | |
+7.34% | 9.03B |
- Stock Market
- Equities
- CANF Stock
- News Can-Fite BioPharma Ltd.
- HC Wainwright Adjusts Can-Fite Biopharma Price Target to $18 From $34, Maintains Buy Rating